Dr Fabio Luciani – A single cell multi-omics approach to understand CAR T cells response in the context of leukaemia

Event type: 
Event date: 
Tuesday, 3 March 2020 - 1:00pm to 2:00pm

Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus, UNSW Sydney

Contact for inquiries: 
Rata Joseph, +61 (2) 9385 0900 or recpt@kirby.unsw.edu.au
Booking deadline: 

Kirby Institute Seminar Series presents

Dr Fabio Luciani

Dr Fabio Luciani

NHMRC Fellow and Associate Professor, Immunovirology and Pathogenesis Program, Kirby Institute

Associate Professor Fabio Luciani is a senior researcher (NHMRC Research Fellow) in Systems Immunology at the School of Medical Sciences and at the Kirby Institute, UNSW Sydney. He trained as a theoretical physicist (Masters, Bologna University Italy) and theoretical immunologist and biophysicist (PhD, Berlin, Germany), and then moved to Australia as a postdoctoral researcher in mathematical modeling of infectious diseases. In 2008, he was awarded an NHMRC Postdoctoral Training Fellow and conducted successfully interdisciplinary research across mathematical modeling, bioinformatics, statistics, genomics, and immunology. His current research focusses on the application of single cell technologies to study T cell responses in the context of viral infections, autoimmunity and novel cellular immunotherapies.


Chimeric antigen receptor (CAR) T cell therapy are “a living drug” that are successfully changing patients care in the context of leukaemia, and hold promises for the treatment of viral infections and solid tumours. Despite revolutionary success with complete remission in up to 90% of treated individuals with relapsed B-cell acute lymphoblastic leukaemia (ALL) early life-threatening toxicities, complex clinical management and loss of function of CAR T cells are limiting the success of these therapies. This presentation features novel and unpublished work on the application of single cell technologies to unravel the complexity of heterogeneity of CAR T cells during therapy. The simultaneous identification of gene and protein expression profiles at the single cell level can be successfully used to characterise the interactions of CAR T cells with other cells of the patient immune system, and to determine the molecular signatures of persisting or exhausted CAR T cells. This novel approach can be used to understand clinical outcome and to develop a therapy response model.